Research by Dr Karen Chung
All of our attendees carry out a piece of research in an area of MS clinical practice or treatment that interests them.
This project was awarded runner up in the MS Academy MasterClass Project Awards Autumn 2018, and this snapshot gives you a quick idea of what Dr Chung found and why. If you want to learn more, just click through to her full slide set, or follow the links within the snapshot.
If you would like to contact the Dr Chung, drop us a line and we’ll put you in touch where possible.
The three-part objective was:
- To estimate the number of people living with primary-progressive multiple sclerosis (PPMS) in the researcher’s department,
- to consider the number who may potentially meet the eligibility criteria for Ocrelizumab and
- to create service plans to support roll out of the drug, if licensed.
- Ocrelizumab is shown to reduce disability progression in people with PPMS, and is being reviewed for license by NICE at present.
- If approved, it will be the first disease-modifying therapy (DMT) for this form of the condition.
- 40 of the 52 PPMS patients reviewed would likely be eligible for Ocrelizumab treatment.
- If made available, there is likely to be an increase in PPMS referrals in the future.
- Findings were gathered via retrospective review of MS clinic notes from Jan-March 2018 and a review of all available electronic clinical notes.
- Of 1082 MS clinic visits, 52 patients had PPMS
- Using eligibility criteria expected across age, EDSS, and disease duration, a potential 40 patients were estimated likely eligible for treatment.
- Prepare for the potential increase in PPMS referrals.
- Await NICE recommendations (due 31 October 2018).
- Read the full report.
- See the full slide set from Dr Chung’s presentation here.
- Contact the researcher to discuss their work (please put the name of the Snapshot as your title in our contact form)
- Learn more about the issues raised in this report. Click the scattered links to access further information.